215 related articles for article (PubMed ID: 29989571)
41. The role of oncolytic virus immunotherapies to subvert cancer immune evasion.
Workenhe ST; Verschoor ML; Mossman KL
Future Oncol; 2015; 11(4):675-89. PubMed ID: 25686121
[TBL] [Abstract][Full Text] [Related]
42. Parainfluenza Virus Infection Sensitizes Cancer Cells to DNA-Damaging Agents: Implications for Oncolytic Virus Therapy.
Fox CR; Parks GD
J Virol; 2018 Apr; 92(7):. PubMed ID: 29343567
[TBL] [Abstract][Full Text] [Related]
43. Combination of Vaccine-Strain Measles and Mumps Viruses Enhances Oncolytic Activity against Human Solid Malignancies.
Son HA; Zhang L; Cuong BK; Van Tong H; Cuong LD; Hang NT; Nhung HTM; Yamamoto N; Toan NL
Cancer Invest; 2018 Feb; 36(2):106-117. PubMed ID: 29485292
[TBL] [Abstract][Full Text] [Related]
44. Recent advances of oncolytic virus in cancer therapy.
Mondal M; Guo J; He P; Zhou D
Hum Vaccin Immunother; 2020 Oct; 16(10):2389-2402. PubMed ID: 32078405
[TBL] [Abstract][Full Text] [Related]
45. Oncolytic parvoviruses as cancer therapeutics.
Rommelaere J; Geletneky K; Angelova AL; Daeffler L; Dinsart C; Kiprianova I; Schlehofer JR; Raykov Z
Cytokine Growth Factor Rev; 2010; 21(2-3):185-95. PubMed ID: 20211577
[TBL] [Abstract][Full Text] [Related]
46. The utility of cells as vehicles for oncolytic virus therapies.
Russell SJ; Peng KW
Curr Opin Mol Ther; 2008 Aug; 10(4):380-6. PubMed ID: 18683103
[TBL] [Abstract][Full Text] [Related]
47. Therapeutic Applications for Oncolytic Self-Replicating RNA Viruses.
Lundstrom K
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555262
[TBL] [Abstract][Full Text] [Related]
48. Newcastle disease virus strain AF2240 as an oncolytic virus: A review.
Kalyanasundram J; Hamid A; Yusoff K; Chia SL
Acta Trop; 2018 Jul; 183():126-133. PubMed ID: 29626432
[TBL] [Abstract][Full Text] [Related]
49. Oncolytic adenoviruses: design, generation, and experimental procedures.
Davydova J; Yamamoto M
Curr Protoc Hum Genet; 2013 Jul; Chapter 12():Unit 12.14. PubMed ID: 23853080
[TBL] [Abstract][Full Text] [Related]
50. Newcastle disease virus: a promising agent for tumour immunotherapy.
Zhao L; Liu H
Clin Exp Pharmacol Physiol; 2012 Aug; 39(8):725-30. PubMed ID: 22211810
[TBL] [Abstract][Full Text] [Related]
51. Virus, Oncolytic Virus and Human Prostate Cancer.
Liu GB; Zhao L; Zhang L; Zhao KN
Curr Cancer Drug Targets; 2017; 17(6):522-533. PubMed ID: 27993115
[TBL] [Abstract][Full Text] [Related]
52. Rethinking herpes simplex virus: the way to oncolytic agents.
Campadelli-Fiume G; De Giovanni C; Gatta V; Nanni P; Lollini PL; Menotti L
Rev Med Virol; 2011 Jul; 21(4):213-26. PubMed ID: 21626603
[TBL] [Abstract][Full Text] [Related]
53. Optimization and preclinical design of genetically engineered viruses for human oncolytic therapy.
Hiss DC; Fielding BC
Expert Opin Biol Ther; 2012 Nov; 12(11):1427-47. PubMed ID: 22788715
[TBL] [Abstract][Full Text] [Related]
54. [Oncolytic virus therapy for malignant brain tumors].
Ino Y; Todo T
Brain Nerve; 2009 Jul; 61(7):815-22. PubMed ID: 19618859
[TBL] [Abstract][Full Text] [Related]
55. Generation of a recombinant oncolytic Newcastle disease virus and expression of a full IgG antibody from two transgenes.
Pühler F; Willuda J; Puhlmann J; Mumberg D; Römer-Oberdörfer A; Beier R
Gene Ther; 2008 Mar; 15(5):371-83. PubMed ID: 18200068
[TBL] [Abstract][Full Text] [Related]
56. Luciferase imaging for evaluation of oncolytic adenovirus replication in vivo.
Guse K; Dias JD; Bauerschmitz GJ; Hakkarainen T; Aavik E; Ranki T; Pisto T; Särkioja M; Desmond RA; Kanerva A; Hemminki A
Gene Ther; 2007 Jun; 14(11):902-11. PubMed ID: 17377596
[TBL] [Abstract][Full Text] [Related]
57. ReVOLT: radiation-enhanced viral oncolytic therapy.
Advani SJ; Mezhir JJ; Roizman B; Weichselbaum RR
Int J Radiat Oncol Biol Phys; 2006 Nov; 66(3):637-46. PubMed ID: 17011442
[TBL] [Abstract][Full Text] [Related]
58. Oncolytic activity of a coxsackievirus B3 strain in human endometrial cancer cell lines.
Lin Y; Wang W; Wan J; Yang Y; Fu W; Pan D; Cai L; Cheng T; Huang X; Wang Y
Virol J; 2018 Apr; 15(1):65. PubMed ID: 29631630
[TBL] [Abstract][Full Text] [Related]
59. JX-594, a targeted oncolytic poxvirus for the treatment of cancer.
Merrick AE; Ilett EJ; Melcher AA
Curr Opin Investig Drugs; 2009 Dec; 10(12):1372-82. PubMed ID: 19943208
[TBL] [Abstract][Full Text] [Related]
60. Oncotargeting by Vesicular Stomatitis Virus (VSV): Advances in Cancer Therapy.
Bishnoi S; Tiwari R; Gupta S; Byrareddy SN; Nayak D
Viruses; 2018 Feb; 10(2):. PubMed ID: 29473868
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
